Proteasome inhibitor for treatment of multiple myeloma
Bortezomib is more effective than high-dose dexamethasone for treatment of patients with relapsed multiple myeloma, according to results from the Assessment of Proteasome Inhibition for Extending Remissions
(2005). Proteasome inhibitor for treatment of multiple myeloma. lancet oncology, 6(8), 546.
Available at: http://ecommons.aku.edu/pakistan_fhs_mc_surg_surg/426